News|Articles|November 21, 2026

Acne Treatment Adherence Ranges From 6% to 84% in Real-World Studies

Fact checked by: Brooke McCormick
Listen
0:00 / 0:00

Key Takeaways

  • Real-world adherence to topical and oral acne regimens was highly variable, and more objective measures (MPR, refills, drug survival) suggested substantial early discontinuation.
  • Study heterogeneity in adherence definitions and instruments prevented meta-analysis and produced divergent estimates, including low MPR-based adherence when dichotomized at ≥0.8.
SHOW MORE

Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.

Acne treatments only work if patients use them for weeks, and a new systematic review suggests that in everyday practice, many do not. Across 26 papers reporting nonrandomized, real-world studies, estimated adherence to oral and topical acne treatments ranged from 6% to 84%, with larger studies landing at roughly 50% to 65%, according to findings published in Skin Health and Disease.1

Why Adherence in Acne Vulgaris Needed a Closer Look

Acne vulgaris affects 90% of teenagers at some point, persists for several years in about half of people, and leads to scarring in approximately 20%. Yet there has been relatively little exploration of whether nonadherence stems mainly from never starting treatment, using it inconsistently, or stopping early.

Current American Academy of Dermatology guidelines give strong recommendations to benzoyl peroxide, topical retinoids, topical antibiotics, oral doxycycline, and, for severe or refractory disease, isotretinoin, while advising clinicians to limit systemic antibiotic use.2 Because those first-line topical options must be used regularly for several weeks to work, the review's authors noted, adherence sits at the center of whether guideline-based care succeeds.1

Review Focused on Real-World, Nonrandomized Acne Studies

The researchers searched MEDLINE, PubMed, Embase, PsycINFO, and CINAHL from inception through March 24, 2025, with no language restrictions. Because a prior review had covered randomized controlled trials, and trial participants are less likely to reflect everyday adherence, this analysis was limited to observational and other nonrandomized designs and excluded studies of isotretinoin alone.

Of 5682 records screened, 26 papers from the Americas, Europe, and Asia met inclusion criteria. Thirteen were descriptive studies that included 8111 survey participants, plus 2 studies drawing on electronic health records, and 13 papers reporting 12 studies used other designs, such as analytic cross-sectional or cohort studies, with 37,884 participants. Because measurement methods differed so widely, the authors did not calculate a pooled estimate.

Acne Adherence Estimates Depended Heavily on How They Were Measured

Twenty-one studies relied on self-report, 3 used medication possession ratio (MPR), which compares days of medication dispensed with days needed, 3 assessed prescription refills, 1 performed a drug survival analysis, and 1 used pill counts and tube weighing; 4 used more than 1 method. The lowest estimates, 6% for oral and 17% for topical treatments, came from a study of 96 adolescents aged 12 to 17 years. When MPR was dichotomized at 0.8 or higher, only about 12% of patients were classified as adherent, and the mean MPR among US Medicaid enrollees was 0.34, compared with 0.65 in a UK dermatology setting.

Other measures pointed to early drop-off. In a Belgian drug survival analysis of more than 1000 patients, the median duration of topical acne treatment was 2 months, and only 50% of patients continued treatment at 3 months. In a US survey, 27% of participants had not filled all prescriptions from their last acne visit.

Younger age, specifically younger than 15 years or younger than 12 years, was associated with lower adherence in 2 large studies, but evidence on differences between men and women was inconsistent. Contrary to a common perception, the review found little consistent evidence that adherence to topical treatments was lower than adherence to oral treatments other than isotretinoin.

Cost, Adverse Effects, and Slow Results Drove Nonadherence

Eight studies reported reasons for nonadherence, most commonly forgetfulness, perceived ineffectiveness, adverse effects, and cost. In a Belgian study of 1029 patients, 52% cited perceived ineffectiveness as the reason for stopping, while only 9% cited controlled acne and 9% cited side effects. In a Turkish study, about 40% of patients who discontinued treatment did so after seeing rapid improvement, a reminder that some nonadherence reflects resolution rather than failure.

“Our findings also point to the clinical importance of addressing treatment adherence in acne, and that potential solutions should be aimed at mitigating against side effects, ensuring that people with acne understand that treatments take several weeks of regular use to take effect, offering tools to support adherence, and offering proactive review,” the researchers wrote.

Industry Links and Inconsistent Measures Limit Conclusions

The authors acknowledged that most included studies had links with pharmaceutical organizations. Eight studies used the industry-supported ECOB questionnaire, which rates adherence as poor if any answer is unexpected, including failing to recall the treatment's name, a method that may favor products with prominent branding rather than reflecting how regularly treatments are used. Most studies also focused on prescribed treatments, so findings may not apply to people who self-manage acne.

For clinicians and payers, access appears to matter: the authors contrasted the high cost and insurance approval process for topical retinoids in the US with the UK, where prescriptions are free for many young and low-income patients. Setting expectations about time to benefit, managing irritation early, and scheduling proactive follow-up may help more patients, especially the youngest, stay on therapy.

References

  1. Santer M, Maund E, Becque T, et al. Treatment adherence in acne vulgaris: systematic review and narrative synthesis. Skin Health Dis. 2026;6(5):690-711. doi:10.1093/skinhd/vzag084
  2. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-1006.e30. doi:10.1016/j.jaad.2023.12.017

Related to this article